Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

<p>Table S3: GO analysis of phosphorylated proteins differentially expressed in αEPHA2-Cond and cIgG-Tr cells.</p>

Enregistré dans:

Détails bibliographiques
Auteur principal:	Amr El Zawily (14851115) (author)
Autres auteurs:	Frederick S. Vizeacoumar (14851118) (author), Renuka Dahiya (14851121) (author), Sara L. Banerjee (14851124) (author), Kalpana K. Bhanumathy (14851127) (author), Hussain Elhasasna (14851130) (author), Glinton Hanover (14851133) (author), Jessica C. Sharpe (14851136) (author), Malkon G. Sanchez (14851139) (author), Paul Greidanus (14851142) (author), R. Greg Stacey (14851145) (author), Kyung-Mee Moon (14851148) (author), Ilya Alexandrov (14851151) (author), Juha P. Himanen (14851154) (author), Dimitar B. Nikolov (14851157) (author), Humphrey Fonge (14851160) (author), Aaron P. White (14851163) (author), Leonard J. Foster (8976302) (author), Bingcheng Wang (14851166) (author), Behzad M. Toosi (14851169) (author), Nicolas Bisson (14851172) (author), Tajib A. Mirzabekov (14851175) (author), Franco J. Vizeacoumar (14851178) (author), Andrew Freywald (14851181) (author)
Publié:	2025
Sujets:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology Computational Methods Database resources Drug Targets Cell surface receptor drug targets Proteomics Systems Biology Translational Research
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires